HIV accessory proteins as therapeutic targets.
Miller
R H
RH
Targeted Interventions Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892-7620, USA.
Sarver
N
N
D016915:AIDS Vaccines; D015195:Drug Design; D015693:Gene Products, nef / Q000187:drug effects / Q000378:metabolism; D016346:Gene Products, vif / Q000187:drug effects / Q000378:metabolism; D016336:Gene Products, vpr / Q000187:drug effects / Q000378:metabolism; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000187:drug effects / Q000378:metabolism*; D054298:Human Immunodeficiency Virus Proteins; D019444:Vaccines, DNA; D054334:Viral Regulatory and Accessory Proteins / Q000187:drug effects / Q000378:metabolism*; D054311:nef Gene Products, Human Immunodeficiency Virus; D054320:vif Gene Products, Human Immunodeficiency Virus; D054325:vpr Gene Products, Human Immunodeficiency Virus; D000086082:Viroporin Proteins
D016915:AIDS Vaccines; D015693:Gene Products, nef; D016346:Gene Products, vif; D016336:Gene Products, vpr; D054298:Human Immunodeficiency Virus Proteins; D019444:Vaccines, DNA; D054334:Viral Regulatory and Accessory Proteins; D054311:nef Gene Products, Human Immunodeficiency Virus; D054320:vif Gene Products, Human Immunodeficiency Virus; D054325:vpr Gene Products, Human Immunodeficiency Virus; C514859:vpu protein, Human immunodeficiency virus 1; D000086082:Viroporin Proteins